She was sixty-eight, from a lane off Bemina, and she came to my OPD because she could no longer stand long enough to make her morning tea.
There had been no fall. No accident. She had simply bent over to lift a bucket of water, felt something give way in her back, and by the time her son brought her to me she had lost nearly two inches of height and was walking with the stooped, careful gait I have come to recognise from across the corridor. Her X-ray showed a wedge-shaped D12 vertebra. Her DEXA scan came back with a T-score of −3.8. Her vitamin D was 9 ng/mL.
She had been on a weekly alendronate tablet for four years. She was, on paper, “on treatment.”
She had also, in that time, fractured twice.
In my orthopaedic practice in the Valley, this is the patient I see most often and treat most poorly: the woman with severe, established osteoporosis, already fracturing, already on a bisphosphonate — and still losing bone. For her, an anti-resorptive tablet is not enough. She does not need her bone loss slowed. She needs bone built.
That is the specific job teriparatide does.
First, the problem we are not talking about enough
Osteoporosis in India is not a niche geriatric footnote. It is a public-health blind spot.
| The numbers | What they mean |
|---|---|
| ~50 million Indians estimated to be osteoporotic or have low bone mass (2013 estimates) | Roughly one in twenty of the entire country |
| ~46 million Indian women over 50 estimated to have osteoporosis | The disease is overwhelmingly, though not exclusively, female |
| Hip fractures occur in India a decade earlier than in Western populations | We are fracturing in our sixties, not our seventies |
| >30% one-year mortality after hip fracture in Indian public-hospital settings | A broken hip at 70 is not a broken bone. It is a life-threatening event |
| 83% of apparently healthy Kashmiri adults were vitamin D deficient in one Valley study — and ~94% of the women | Despite our famous sunshine |
That last row deserves its own paragraph, because it is ours.
A study of healthy adults in the Kashmir Valley found vitamin D deficiency in the overwhelming majority — with women faring dramatically worse than men. A later SKIMS-led study of 270 volunteers found roughly 65% of men and 88% of women deficient. We live at 34° north, we spend four months of the year indoors around a bukhari, our clothing covers most of our skin, and our dietary calcium intake is low. The sun over Dal Lake is not reaching most of our patients’ skin, and it never has.
This is the soil in which osteoporosis grows here. And it is why, by the time many of my patients arrive with a fragility fracture, their skeleton is in far worse condition than their age alone would predict.
What teriparatide actually is (and why the injection has to be daily)
Teriparatide is a recombinant fragment of human parathyroid hormone — specifically the first 34 amino acids, PTH(1–34). It is given as a 20 microgram subcutaneous injection, once a day, using a pre-filled pen.
Now, here is the part that patients find counter-intuitive, and that I spend a good five minutes explaining in every consultation.
Parathyroid hormone is the hormone that dissolves bone. In hyperparathyroidism — where PTH levels stay continuously high — the skeleton is stripped of calcium. So why on earth would we inject it into someone with osteoporosis?
Because the skeleton does not respond to how much PTH there is. It responds to how it arrives.
Continuous PTH exposure breaks bone down. Brief, once-daily pulses build it up. A short daily spike stimulates osteoblasts — the bone-forming cells — before the bone-resorbing osteoclasts can fully mobilise. That narrow window is called the anabolic window, and it is the entire therapeutic principle behind this drug.
This makes teriparatide fundamentally different from everything else in the osteoporosis cupboard. Alendronate, risedronate, zoledronic acid, denosumab — these are anti-resorptive. They are brakes. They stop you losing what you have.
Teriparatide is an anabolic. It is an accelerator. It lays down new bone matrix, thickens trabeculae, and improves the internal architecture of the vertebral body — not just the number on the DEXA report.
For a patient who has already fractured, that distinction is everything.
The evidence, in plain language
I am wary of blog posts that wave vaguely at “studies show.” Here is what the actual trials found.
The Fracture Prevention Trial (Neer et al., New England Journal of Medicine, 2001). This is the pivotal study — 1,637 postmenopausal women with at least one existing vertebral fracture, followed for a median of about 21 months. Compared with placebo, daily 20 mcg teriparatide reduced:
- New vertebral fractures by 65%
- Non-vertebral fragility fractures by 53%
Lumbar spine bone mineral density rose by roughly 9%, and femoral neck BMD by about 3%.
The VERO trial (Kendler et al., The Lancet, 2018). This one matters more to me clinically, because it is not a placebo comparison — it is a head-to-head fight. 1,360 postmenopausal women with severe osteoporosis were randomised to daily teriparatide or weekly risedronate for 24 months. The results:
| Outcome at 24 months | Teriparatide | Risedronate |
|---|---|---|
| New vertebral fractures | 5.4% | 12.0% |
| Clinical fractures | 4.8% | 9.8% |
| Non-vertebral fragility fractures | 4.0% | 6.1% (not statistically significant) |
That is roughly a 56% reduction in new vertebral fractures compared not to nothing, but to a real, active, widely-prescribed osteoporosis drug. Notably, the curves separated early — the biggest divergence appeared in the 6-to-12-month window.
When I show my patients that table, the daily injection stops feeling like a punishment and starts feeling like a decision.
So who should actually be on it?
Teriparatide is not a first-line drug for a 55-year-old with mild osteopenia. It is expensive, it is a daily needle, and it is reserved for people whose skeleton is genuinely in trouble.
In my practice, I consider it for:
- Severe osteoporosis with existing fragility fracture(s) — particularly vertebral fractures, and especially multiple ones
- Very low T-scores (typically ≤ −3.0, or ≤ −2.5 with a fracture)
- Patients who keep fracturing despite adequate bisphosphonate or denosumab therapy — treatment failure
- Glucocorticoid-induced osteoporosis — the patient on long-term steroids for rheumatoid arthritis, asthma, or a transplant, where bone formation is directly suppressed
- Patients who cannot tolerate oral bisphosphonates — significant reflux, oesophageal disease, or an inability to sit upright for 30 minutes
- Occasionally, non-union or delayed union of certain fractures, and select cases of atypical femoral fracture — used off-label, and with careful counselling
Who should not receive it
This list is short, and it is non-negotiable:
- Pre-existing hypercalcaemia or primary hyperparathyroidism
- Skeletal malignancy or bone metastases
- Paget’s disease of bone, or unexplained raised alkaline phosphatase
- Prior external-beam or implant radiation to the skeleton
- Open epiphyses — children and growing adolescents
- Pregnancy and breastfeeding
- Severe renal impairment, and active urolithiasis, warrant real caution
The osteosarcoma question — let’s settle it
Almost every patient who reads about teriparatide online arrives at my next appointment frightened of the same word: cancer.
Here is the honest history. In the original toxicology work, rats given very high doses for nearly their entire lifespan developed osteosarcoma. That finding earned the drug a boxed warning and a strict 24-month lifetime cap when it was approved in 2002.
Then we watched. For fifteen years, across large post-marketing surveillance programmes and cancer-registry linkage studies, researchers looked for a signal in human beings.
They did not find one. Osteosarcoma rates in teriparatide-treated adults matched the expected background rate.
In November 2020, the US FDA removed the osteosarcoma boxed warning from the teriparatide label and revised the two-year lifetime limitation on treatment. The rat data was a rat-shaped answer to a rat-shaped question. It did not translate to humans.
That said, I still generally treat for 18 to 24 months in routine practice, because that is where the fracture-reduction evidence is strongest and where the anabolic effect is most pronounced. Extended courses are now permissible, but they are a considered, individualised decision — not a default.
The rule that actually decides whether this works
If you take one clinical fact away from this article, make it this one.
Teriparatide’s gains are not permanent. The new bone you build over 18–24 months will be lost — often quickly — unless you follow the course with an anti-resorptive drug to lock it in.
I cannot overstate how many patients I have inherited from elsewhere who completed an expensive, disciplined, 18-month course of daily injections… and then simply stopped. No bisphosphonate afterwards. No denosumab. Nothing.
Within two years, most of that hard-won bone was gone. Twelve months of daily needles and several lakh rupees, undone by a missing follow-on prescription.
There is also an ordering effect worth knowing: starting teriparatide after prolonged bisphosphonate therapy can blunt the early bone-building response, particularly at the hip. And in patients already on denosumab, transitioning must be handled with real care — abrupt denosumab withdrawal carries a genuine risk of rebound vertebral fractures.
Sequence is not a detail. Sequence is the treatment.
The practical realities — what nobody warns you about
Storage and the Kashmir cold chain. The pen must be kept refrigerated at 2–8°C, and it must never freeze. In a Srinagar winter with long power cuts, I have had patients store the pen on a windowsill “because it’s cold anyway” and destroy several thousand rupees of medication in a single night. Refrigerator. Not the bukhari room. Not the balcony. Once a pen is in use, it is typically discarded after 28 days.
The first injection. Transient dizziness and a drop in blood pressure can occur, particularly with the first few doses. I ask patients to take the first injection sitting down or lying on the bed, at home, in the evening — and to stay put for a few minutes afterwards.
Common side effects. Nausea, leg cramps, headache, injection-site redness, and mild transient hypercalcaemia. In the pivotal trial, only about 11% developed transient hypercalcaemia, and it almost always settled without intervention. I check serum calcium before starting and again about a month in.
Before the first dose, always: correct the vitamin D. Correct the calcium. Rule out hyperparathyroidism and hypercalcaemia. Check renal function. Starting teriparatide in a patient with a vitamin D of 9 ng/mL is like laying bricks with no mortar.
Cost. In India, teriparatide biosimilar pens typically run in the region of ₹4,000–₹6,000 for a month of therapy, though prices vary by brand and pharmacy — the originator product costs several times that. Over 18–24 months, this is a serious financial commitment for a Kashmiri family, and I say so out loud in the consultation. Pretending otherwise helps nobody.
What teriparatide will not do for you
It will not stop you falling on black ice outside your gate in January.
A drug that reduces vertebral fracture risk by 65% is remarkable. It is also useless if the patient goes down a wet staircase in the dark. Fracture prevention in the Valley is at least half an environmental problem:
- Fall-proof the home — loose rugs, unlit staircases, wet bathroom floors, and trailing wires cause more fractures in my OPD than any T-score.
- Fix the vitamin D and calcium properly, and re-test. Our home blood test service exists precisely because the elderly patients who most need a 25(OH)D level are the least able to queue at a lab. Browse the full diagnostic test list to see what can be collected at home.
- Keep the muscles working. Bone follows muscle. Supervised, weight-bearing rehabilitation — especially after a fracture — is not optional, and our home physiotherapy service reaches patients who cannot get to a clinic.
- Winter is the danger season. Our Chilla Kalan winter health guide covers exactly this period, when falls, immobility, and sunlight deprivation compound each other.
- Watch for the warning signs in your parents. Height loss, a new stoop, back pain that came from nothing — these are fractures until proven otherwise. This piece on the signs an elderly parent needs home care is worth reading before a crisis, not after.
For patients who struggle with the daily injection — and elderly patients with arthritic hands or poor eyesight genuinely do — a trained nurse can teach and supervise technique at home. That is exactly the sort of thing our home nursing team and elderly care service handle, and it is often the difference between a completed course and an abandoned one.
Frequently asked questions
How long does teriparatide take to work?
Bone formation markers rise within weeks, but meaningful BMD change takes months. In the VERO trial, the fracture-reduction advantage over risedronate was already visible within 6–12 months.
Is it better than a bisphosphonate?
For severe osteoporosis with existing fractures — the evidence says yes, for vertebral and clinical fractures. For mild osteopenia in a low-risk patient, a bisphosphonate remains the sensible, affordable first choice. Different drugs for different skeletons.
Can I stop when I feel better?
There is nothing to feel. Osteoporosis is silent until it breaks. Stopping early — and especially stopping without a follow-on anti-resorptive — wastes the entire course.
Does it repair a fracture that has already happened?
It cannot un-wedge a collapsed vertebra. It reduces the risk of the next one. In practice, many patients also report meaningful improvement in chronic back pain, likely because they stop accumulating new micro-fractures.
Can men take it?
Yes. Teriparatide is approved for men with osteoporosis at high fracture risk, and for glucocorticoid-induced osteoporosis in both sexes. Male osteoporosis is badly underdiagnosed here — around a third of Indian men over 50 are estimated to be affected.
Back to Bemina
She completed eighteen months. She injected every evening after Maghrib, and her son marked each one on a calendar taped inside the kitchen cupboard. Her repeat DEXA showed a lumbar spine T-score improvement of a little over one full standard deviation. We transitioned her to a bisphosphonate to hold the gains.
She has not fractured since. She makes her own tea.
I am not telling you this because teriparatide is a miracle — it is not, and I would distrust anyone who called it one. I am telling you because for the specific patient in front of me that day, the correct drug existed, and for four years nobody had offered it to her.
If you or a parent in Kashmir has fractured from a minor fall, has lost height, or has a DEXA T-score below −2.5, please do not accept “take this calcium tablet” as a complete answer. Ask specifically: am I a candidate for anabolic therapy?
The bone you build in your seventies is the bone that carries you through your eighties.
Get assessed at home
If leaving the house is difficult — and after a vertebral fracture, it usually is — Kashmir Health Collective can arrange a doctor’s home visit, home blood collection for vitamin D, calcium and bone profile, and home physiotherapy across Srinagar and the wider Valley.
Medical disclaimer: This article is for education, not prescription. Teriparatide is a specialist, prescription-only drug with important contraindications, and it is not appropriate for everyone with low bone density. Please do not start, stop, or switch osteoporosis therapy without an in-person assessment by a qualified clinician. Patient details in this article have been altered and combined to protect privacy.
Written for the Kashmir Health Journal.
Key references: Neer RM et al., N Engl J Med 2001;344:1434–41 · Kendler DL et al. (VERO), The Lancet 2018;391:230–40 · Krege JH et al., JBMR Plus 2022;6:e10665 (FDA label revision) · Zargar AH et al., Postgrad Med J 2007;83:713–16 (vitamin D status in Kashmir) · IOF Asia-Pacific Regional Audit: India, 2013